UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 284

Sortiert nach

Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study

Annals of oncology, 2018-11, Vol.29, p.ix35-ix36

2018

Link zum Volltext

Verfügbarkeit prüfen

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

Annals of oncology, 2021-09, Vol.32 (9), p.1157-1166

2021

Link zum Volltext

Verfügbarkeit prüfen

1522P Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial

Annals of oncology, 2023-10, Vol.34, p.S857-S857

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized clinical trial of an individualized intervention promotes cancer patients’ prognostic awareness and reduces CPR received in the last month

Annals of oncology, 2018-10, Vol.29, p.viii549-viii549

2018

Link zum Volltext

Verfügbarkeit prüfen

142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial

Annals of oncology, 2022-09, Vol.33, p.S604

2022

Link zum Volltext

Verfügbarkeit prüfen

Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice

Annals of oncology, 2019-04, Vol.30, p.ii6-ii6

2019

Link zum Volltext

Verfügbarkeit prüfen

172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial

Annals of oncology, 2023-11, Vol.34, p.S1542-S1543

2023

Link zum Volltext

Verfügbarkeit prüfen

Personalized prognostic model incorporating axillary lymph node ratio and molecular subtype for predicting long-term survival in node-positive patients with breast cancer: A large-scale, multicenter study

Annals of oncology, 2018-11, Vol.29, p.ix1-ix1

2018

Link zum Volltext

Verfügbarkeit prüfen

LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial

Annals of oncology, 2023-10, Vol.34, p.S1299-S1299

2023

Link zum Volltext

Verfügbarkeit prüfen

VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Annals of oncology, 2024-03, Vol.35 (3), p.332-333

2024

Link zum Volltext

Verfügbarkeit prüfen

Prognostic nomograms for predicting overall and cancer-specific survival in breast cancer patients not achieving pathological complete response after neoadjuvant chemotherapy

Annals of oncology, 2018-11, Vol.29, p.ix8-ix8

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic nomogram based on lymph node ratio to predict survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy

Annals of oncology, 2018-11, Vol.29, p.ix8-ix8

2018

Link zum Volltext

Verfügbarkeit prüfen

74P Characterization of ERBB2 variation and their association with immune response in solid tumours

Annals of oncology, 2023-10, Vol.34, p.S209-S209

2023

Link zum Volltext

Verfügbarkeit prüfen

Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells

Annals of oncology, 2018-10, Vol.29, p.viii679-viii679

2018

Link zum Volltext

Verfügbarkeit prüfen

The landscape of kinase fusions in 445 Chinese NSCLC patients

Annals of oncology, 2017-10, Vol.28, p.vii16-vii16

2017

Link zum Volltext

Verfügbarkeit prüfen

C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer

Annals of oncology, 2018-10, Vol.29, p.viii388-viii388

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study

Annals of oncology, 2018-10, Vol.29, p.viii210-viii210

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of oncology, 2022-08, Vol.33 (8), p.814-823

2022

Link zum Volltext

Verfügbarkeit prüfen

NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Annals of oncology, 2018-10, Vol.29, p.viii249-viii250

2018

Link zum Volltext

Verfügbarkeit prüfen

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study

Annals of oncology, 2018-10, Vol.29, p.viii409-viii409

2018

Link zum Volltext

Verfügbarkeit prüfen

406P Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan

Annals of oncology, 2022-09, Vol.33, p.S722

2022

Link zum Volltext

Verfügbarkeit prüfen

377P Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study

Annals of oncology, 2022-11, Vol.33, p.S1589

2022

Link zum Volltext

Verfügbarkeit prüfen

49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer

Annals of oncology, 2021-09, Vol.32, p.S377-S377

2021

Link zum Volltext

Verfügbarkeit prüfen

568P First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer

Annals of oncology, 2022-09, Vol.33, p.S807

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii493-viii493

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 284

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaLife Sciences & Biomedicine

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(284)

Publikationsform

Artikel
(284)

Sprache

Englisch
(284)

Erscheinungsjahr

n.n

Thema

Breast Cancer
(2)
Humans
(2)
Abstracts
(1)
Adjuvant Therapy
(1)
Androgen Antagonists - Therapeutic Use
(1)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1)
Asian
(1)
Biomarker
(1)
Brca1 Protein - Genetics
(1)
Brca1/2
(1)
Breast Neoplasms - Drug Therapy
(1)
Breast Neoplasms - Genetics
(1)
Decipher
(1)
Docetaxel
(1)
Docetaxel - Therapeutic Use
(1)
Egfr Mutation-Positive
(1)
Erlotinib
(1)
Female
(1)
First-Line
(1)
Gene Expression Profiling
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(284)
Ovid SocietyJournals and Single Titles
(284)
IngentaConnect_期刊（NSTL购买）
(43)
MEDLINE
(2)

Menü

Weitere Dienste

Einstellungen

Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

1522P Camrelizumab plus chemotherapy versus concurrent chemoradiotherapy as neoadjuvant therapy for resectable thoracic oesophageal squamous cell cancer (REVO): A multicenter, randomized, open-label, phase II trial

Randomized clinical trial of an individualized intervention promotes cancer patients’ prognostic awareness and reduces CPR received in the last month

142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial

Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice

172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial

Personalized prognostic model incorporating axillary lymph node ratio and molecular subtype for predicting long-term survival in node-positive patients with breast cancer: A large-scale, multicenter study

LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial

VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Prognostic nomograms for predicting overall and cancer-specific survival in breast cancer patients not achieving pathological complete response after neoadjuvant chemotherapy

Prognostic nomogram based on lymph node ratio to predict survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy

74P Characterization of ERBB2 variation and their association with immune response in solid tumours

Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells

The landscape of kinase fusions in 445 Chinese NSCLC patients

C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer

Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study

406P Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan

377P Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study

49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer

568P First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

Aktive Filter

Suchergebnisse filtern